Cantor Fitzgerald Starts Marker Therapeutics (MRKR) at Overweight

March 18, 2021 4:03 PM EDT
Get Alerts MRKR Hot Sheet
Price: $2.28 +10.14%

Rating Summary:
    7 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 10 | New: 17
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Marker Therapeutics (NASDAQ: MRKR) with a Overweight rating and a price target of $6.00.

The analyst comments "Marker is a clinical-stage biotechnology company focusing on novel T-cell immunotherapies centered around the Multiple Tumor-Associated Antigen (MultiTAA) therapy platform. We believe Marker is undervalued given the potential of this technology to 1) target multiple antigens (potential to enhance tumor-destroying capabilities); 2) allow for a safer profile (no genetic modification is required); 3) increase durability (as a result of greater targeting and epitope spreading); and 4) allow for a more simplistic manufacturing process (a key area we believe the FDA is focused on; this could also lead to lower costs)."

For an analyst ratings summary and ratings history on Marker Therapeutics click here. For more ratings news on Marker Therapeutics click here.

Shares of Marker Therapeutics closed at $1.88 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Comments, Hot New Coverage, New Coverage

Related Entities

Cantor Fitzgerald, FDA